• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

Introduction to 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine (CAS No. 873792-88-2)

4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine, identified by the Chemical Abstracts Service registry number CAS No. 873792-88-2, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the pyrrolopyrimidine class, a structural motif widely recognized for its biological activity and potential therapeutic applications. The presence of both chloro and iodo substituents in its molecular framework makes it a valuable scaffold for further chemical modifications, enabling the development of novel derivatives with enhanced pharmacological properties.

The pyrrolo[2,3-d]pyrimidine core is a privileged structure in drug discovery, exhibiting a broad spectrum of biological activities, including antiviral, anticancer, and anti-inflammatory effects. The specific arrangement of nitrogen atoms in this bicyclic system facilitates interactions with biological targets, making it an attractive scaffold for designing small-molecule inhibitors. In particular, the 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine derivative has been explored for its potential in modulating key enzymes and receptors involved in disease pathways.

Recent advancements in medicinal chemistry have highlighted the importance of halogenated pyrrolopyrimidines in drug development. The chloro and iodo substituents not only enhance the metabolic stability of the compound but also serve as handles for further functionalization via cross-coupling reactions. These reactions are pivotal in constructing more complex molecular architectures, which can lead to improved binding affinity and selectivity against biological targets. For instance, palladium-catalyzed coupling reactions have been employed to introduce diverse pharmacophores at the 4-Chloro and 5-Iodo positions, generating libraries of derivatives for high-throughput screening.

One of the most compelling aspects of 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine is its potential application in the development of targeted therapies. Studies have demonstrated that this compound can interact with specific proteins and enzymes implicated in cancer progression. The chloro group at the 4-position facilitates hydrogen bonding interactions with amino acid residues in protein binding pockets, while the iodo substituent at the 5-position allows for further derivatization to optimize binding affinity. Such structural features make it a promising candidate for designing inhibitors of kinases and other enzymes overexpressed in tumor cells.

In addition to its role as a pharmacophore, 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine has been investigated for its ability to modulate immune responses. Emerging research suggests that this compound can influence key signaling pathways involved in inflammation and autoimmunity. The pyrrolopyrimidine scaffold is known to interact with receptors and intracellular signaling molecules, thereby modulating immune cell function. The presence of halogen atoms enhances its bioavailability and reduces susceptibility to rapid metabolism, ensuring prolonged exposure to biological targets.

The synthesis of 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine involves multi-step organic transformations that highlight the versatility of heterocyclic chemistry. Key synthetic strategies include cyclization reactions to form the pyrrolopyrimidine ring system followed by halogenation at specific positions. The use of modern catalytic methods has streamlined these processes, allowing for scalable production under mild conditions. Such synthetic approaches are crucial for enabling rapid access to libraries of derivatives for preclinical testing.

Preclinical studies have begun to unravel the pharmacological profile of 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine, revealing its potential as a lead compound for drug development. In vitro assays have shown that this compound exhibits inhibitory activity against several kinases relevant to cancer therapy. Moreover, its ability to cross the blood-brain barrier suggests potential applications in treating neurological disorders. These findings underscore the importance of halogenated pyrrolopyrimidines as a class of compounds with diverse therapeutic applications.

The future direction of research on 4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-amine lies in exploring its mechanism of action and optimizing its pharmacokinetic properties. Advances in computational chemistry and structure-based drug design are expected to accelerate the discovery process by predicting how structural modifications will affect biological activity. Additionally, combination therapies involving this compound with other drugs may enhance therapeutic outcomes by targeting multiple disease pathways simultaneously.

In conclusion,4-Chloro-5-Iodo-N-(1H-indolizinyl)-1-(trifluoromethyl)benzamide CAS No 8737919208is a versatile heterocyclic compound with significant potential in pharmaceutical research and drug development.* Its unique structural features,* including halogenated substituents,* make it an attractive scaffold for designing novel therapeutics.* Ongoing studies*are expected*to uncover*more*about*its*biological activity*and*pharmacological properties,*leading*to*new*treatments*for various diseases.*The progress made so far highlights*the importance*of continued research*and innovation*in this field.*

• 123148-78-7(4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine)
• 1060815-92-0(4-Chloro-5-iodo-2-methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 1012785-51-1(2,4-Dichloro-5-iodo-7H-pyrrolo[2,3-D]pyrimidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)